AI assistant
EKF DIAGNOSTICS HOLDINGS PLC Director's Dealing 2021
7617_dirs_2021-11-08_e3f561a8-7e74-49ca-96ea-0134a70ccf8b.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6822R
EKF Diagnostics Holdings PLC
08 November 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director/PDMR Shareholding
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that it has been notified that on 8 November 2021 Julian Baines, Non-Executive Deputy Chairman, sold a total of 250,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 80.76 pence per Ordinary Share.
Following this transaction, Julian Baines' total direct and indirect interest in the Group is 1,605,288 Ordinary Shares representing approximately 0.35% of the Group's total issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | ||
| Christopher Mills, Non-executive Chairman | Tel: +44 (0)29 2071 0570 | ||
| Mike Salter, CEO | |||
| Richard Evans, FD & COO | |||
| Singer Capital Markets (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7496 3000 | ||
| Aubrey Powell / George Tzimas / Tom Salvesen | |||
| Investec Bank plc (Joint Broker) | Tel: +44 (0)20 7597 4000 | ||
| Gary Clarence / Daniel Adams | |||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or [email protected] | ||
| Paul McManus / Lianne Applegarth | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Julian Baines | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Deputy Chairman | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | EKF Diagnostics Holdings plc | |||
| b) | LEI | 213800DXTF3EAUK1AR05 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||
| Identification code | GB0031509804 | ||||
| b) | Nature of the transaction | Sale of Ordinary Shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 80.76p | 250,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A - Single Transaction | ||||
| - Price | |||||
| e) | Date of the transaction | 8 November 2021 | |||
| f) | Place of the transaction | London Stock Exchange - AIMX |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBDBDBSUGDGBI